These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
186 related items for PubMed ID: 15977716
1. [Improved treatment of Crohn's disease]. Nau JY. Rev Med Suisse; 2005 May 04; 1(18):1241. PubMed ID: 15977716 [No Abstract] [Full Text] [Related]
2. Mesalamine derivatives in the treatment of Crohn's disease. Harrell LE, Hanauer SB. Gastroenterol Clin North Am; 2004 Jun 04; 33(2):303-17, ix-x. PubMed ID: 15177540 [Abstract] [Full Text] [Related]
3. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease. Feagan BG. Eur J Surg; 1998 Dec 04; 164(12):903-9. PubMed ID: 10029385 [No Abstract] [Full Text] [Related]
4. Presentation of Crohn's disease as metastatic cutaneous non-caseating granulomatous lesions. Delgado J, Delgado B, Sztarkier I, Cagnano E, Sperber AD, Fich A. Isr Med Assoc J; 2003 Dec 04; 5(12):897-8. PubMed ID: 14689766 [No Abstract] [Full Text] [Related]
6. The suspension of an announced trial on relapse prevention in Crohn's ileitis with a 5-ASA formulation in microgranular form. Prantera C, Bellinvia S. Dig Liver Dis; 2005 Feb 04; 37(2):135-6. PubMed ID: 15733528 [No Abstract] [Full Text] [Related]
13. [Mesalazine is without clinical effect in patients with Crohn disease]. Munck LK. Ugeskr Laeger; 2005 Jan 17; 167(3):302-3. PubMed ID: 15704804 [No Abstract] [Full Text] [Related]
14. Severe exudative ascites as an initial presentation of Crohn's disease. Tekin F, Vatansever S, Ozütemiz O, Musoğlu A, Ilter T. Turk J Gastroenterol; 2005 Sep 17; 16(3):171-3. PubMed ID: 16245232 [Abstract] [Full Text] [Related]
18. The case against using 5-aminosalicyclates in Crohn's disease: con. Stange EF. Inflamm Bowel Dis; 2005 Jun 17; 11(6):613-5. PubMed ID: 15905711 [No Abstract] [Full Text] [Related]